Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

Shelley Wood

November 02, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

Todd Neale

September 20, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Conference News ESC Heart Failure 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

Shelley Wood

June 30, 2021

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Pneumonia in HF Patients Is Common, Lethal, and Preventable

L.A. McKeown

April 19, 2021

News Daily News

Patient-Reported Outcomes Beat NYHA Class for Tracking Gains in HFrEF

L.A. McKeown

March 25, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

Advertisement

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Canagliflozin Improves Quality of Life in HF Patients

TCTMD’s Top 10 Most Popular Stories for October 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

TCTMD’s Top 10 Most Popular Stories for September 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

July/August 2021 News Roundup

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

FDA Approves Dapagliflozin for CKD Patients

Pneumonia in HF Patients Is Common, Lethal, and Preventable

Patient-Reported Outcomes Beat NYHA Class for Tracking Gains in HFrEF

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

FDA Approves Vericiguat for High-risk Patients With HF

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content